ESMO 2025: Latest developments in endometrial cancer

ESMO 2025: Highlights and analysis

Best practice in precision medicine for prostate cancer

ESMO 2025: Latest in EGFR mutant NSCLC

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors

Latest advances in chronic lymphocytic leukaemia

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers

Laser oncosurgery - A new perspective in treating cancer

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy